Publications by authors named "Daniel Ceballos"

Claim this Profile
H
Healthcare professionals' experience with oral oligomeric supplements in malnourished patients in Spain: S-QUEST Study.
Daniel Ceballos, Pablo B Pedrianes Martín, María Lorente, Ignacio García-Puente, Blas Labrador

Rev Esp Enferm Dig· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive proteomic profile in newly diagnosed patients with inflammatory bowel disease: identification of potential biomarkers.
Montse Baldán-Martín, Ibon Iloro, Mikel Azkargorta, Irene Soleto, Macarena Orejudo, Daniel Ceballos

J Crohns Colitis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU.
María José Casanova, Cristina Rubín de Célix, Sabino Riestra, Alfredo J Lucendo, José Manuel Benítez, Daniel Ceballos

Aliment Pharmacol Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploration of fecal microbiota in newly diagnosed patients with inflammatory bowel disease using shotgun metagenomics.
Macarena Orejudo, Manuel J Gómez, Sabino Riestra, Montserrat Rivero, Ana Gutiérrez, Daniel Ceballos

Front Cell Infect Microbiol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Digestive disease in individuals living with obesity: beyond weight loss.
Javier Crespo, Fernando Alberca, Marta Alonso-Peña, Federico Argüelles, Ramón Bataller, Daniel Ceballos

Rev Esp Enferm Dig· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
Javier P Gisbert, María G Donday, Sabino Riestra, Alfredo J Lucendo, José-Manuel Benítez, Daniel Ceballos

Gut· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment Persistence.
Antonio Giordano, Isabel Pérez-Martínez, Javier P Gisbert, Elena Ricart, María Dolores Martín-Arranz, Daniel Ceballos

Am J Gastroenterol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU.
María José Casanova, Berta Caballol, María José García, Francisco Mesonero, Cristina Rubín de Célix, Daniel Ceballos

Dig Liver Dis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study.
María Chaparro, Sandra Hermida, Diana Acosta, Agnès Fernández-Clotet, Manuel Barreiro-de Acosta, Daniel Ceballos

Aliment Pharmacol Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Approach to STRIDE-II in Real-Life Settings: Analysis and Practical Recommendations.
Elena Ricart, Guillermo Bastida, Daniel Carpio, Daniel Ceballos, Daniel Ginard

Crohns Colitis 360· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Experience of Tofacitinib Use in Pregnancy in Patients with Ulcerative Colitis.
María Chaparro, Daniel Ceballos, Raquel Vicente, Javier P Gisbert

Clin Drug Investig· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients.
Laila Aldars-García, Rubén Gil-Redondo, Nieves Embade, Sabino Riestra, Montserrat Rivero, Daniel Ceballos

Inflamm Bowel Dis· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Controversies in the management of anti-TNF therapy in patients with Crohn's disease: a Delphi consensus.
Yago González-Lama, Elena Ricart, Daniel Carpio, Guillermo Bastida, Daniel Ceballos

BMJ Open Gastroenterol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of Spanish gastroenterology units before and after the COVID-19 pandemic: an assessment using the EFIC_AD tool, developed by the Sociedad Española de Patología Digestiva (SEPD).
Elvira Poves, Fernando Carballo, Daniel Ceballos, Fernando Alberca de Las Parras

Rev Esp Enferm Dig· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study.
Ignacio Marín-Jiménez, Manuel Barreiro-de Acosta, María Esteve, Luisa Castro-Laria, Santiago García-López, Daniel Ceballos

Gastroenterol Hepatol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diet and microbiome in the beginning of the sequence of gut inflammation.
Daniel Ceballos, A Hernández-Camba, Laura Ramos

World J Clin Cases· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors: How to Approach the Individualization of Treatment.
Daniel Ceballos

Inflamm Bowel Dis· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive factors of clinical response to treatment with anti-TNF agents in ulcerative colitis: what have we learned from our patients?
Laura Ramos, Alejandro Hernández Camba, Raquel de la Barreda Heusser, Milagros Vela, Inmaculada Alonso-Abreu, Daniel Ceballos

Rev Esp Enferm Dig· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sleep Quality, Quality of Life, and Patient-Reported Outcomes.
Daniel Ceballos

Inflamm Bowel Dis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Harvey-Bradshaw Index Adapted to a Mobile Application Compared with In-Clinic Assessment: The MediCrohn Study.
Ana Echarri, Isabel Vera, Virginia Ollero, Claudia Arajol, Sabino Riestra, Daniel Ceballos

Telemed J E Health· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain.
María Chaparro, Manuel Barreiro-de Acosta, José Manuel Benítez, José Luis Cabriada, María José Casanova, Daniel Ceballos

Therap Adv Gastroenterol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial.
Carlos Taxonera, Antonio López-Sanromán, Isabel Vera-Mendoza, Eugeni Domènech, Vicente Vega Ruiz, Daniel Ceballos

Dig Liver Dis· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial.
Antonio López-Sanromán, Isabel Vera-Mendoza, Eugeni Domènech, Carlos Taxonera, Vicente Vega Ruiz, Daniel Ceballos

J Crohns Colitis· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical status, quality of life, and work productivity in Crohn's disease patients after one year of treatment with adalimumab.
Cristina Saro, Daniel Ceballos, Fernando Muñoz, Cristóbal de la Coba, María Dolores Aguilar

Rev Esp Enferm Dig· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ozone Therapy in the Management of Persistent Radiation-Induced Rectal Bleeding in Prostate Cancer Patients.
Bernardino Clavo, Norberto Santana-Rodriguez, Pedro Llontop, Dominga Gutierrez, Daniel Ceballos

Evid Based Complement Alternat Med· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis